ERNA — Ernexa Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Eterna Therapeutics Announces Research Collaboration To Develop Advanced Gene-Edited Ips Cell Therapies
Eterna Therapeutics jumps on cancer therapy options agreement
Brief: Eterna Therapeutics Completes Name Change, Acquires Option To License Nk And T Cell Therapies From Exacis Biotherapeutics
Brief: Brooklyn Immunotherapeutics Announces Name Change To Eterna Therapeutics
Brief: Brooklyn Immunotherapeutics Inc- On Sept 9, Co Entered Into A Master Services Agreement With Factor Bioscience Inc.
Swiss stocks - Factors to watch on August 19
Brief: Brooklyn Immunotherapeutics Announces Results Of Phase 2 Study Of IRX-2 In Head And Neck Cancer
Brief: Brooklyn ImmunoTherapeutics - Announces Receipt Of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Brief: Brooklyn ImmunoTherapeutics Announces Changes To Executive Management
Brief: Brooklyn Immunotherapeutics Announces Receipt Of Notice From Nasdaq
Brief: Brooklyn Immunotherapeutics Inc Files For Offering Of Up To 13.7 Shares Of Common Stock By The Selling Stockholder - SEC Filing
U.S. RESEARCH ROUNDUP- Airbnb, Exelon, Netflix
Brooklyn Immunotherapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brooklyn Immunotherapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Brooklyn Immunotherapeutics Announces Closing Of $12 Mln Private Placement
Brief: Brooklyn Immunotherapeutics Announces $12 Mln Private Placement
Brooklyn Immunotherapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Brooklyn Immunotherapeutics Inc - Expanded Board Size From Five To Six Directors
Brief: Brooklyn Immunotherapeutics Welcomes Erin S. Enright And Heather B. Redman To Its Board Of Directors